Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMMU.ST
- Price
- 4.80
- Stock movement down
- -0.20 (-3.90%)
- Company name
- Mendus AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 241.73M
- Ent value
- 176.63M
- Price/Sales
- 7.58
- Price/Book
- 0.36
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.42%
- 1 year return
- -54.02%
- 3 year return
- -49.39%
- 5 year return
- -49.45%
- 10 year return
- -38.94%
Last updated: 2025-04-12
DIVIDENDS
IMMU.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.58 |
| Price to Book | 0.36 |
| EV to Sales | 5.54 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.36M |
| EPS (TTM) | -2.76 |
| FCF per share (TTM) | -1.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 31.90M |
| Gross profit (TTM) | 26.60M |
| Operating income (TTM) | -145.19M |
| Net income (TTM) | -138.05M |
| EPS (TTM) | -2.76 |
| EPS (1y forward) | -0.49 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 83.38% |
| Operating margin (TTM) | -455.20% |
| Profit margin (TTM) | -432.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 109.32M |
| Net receivables | 0.00 |
| Total current assets | 156.78M |
| Goodwill | 108.35M |
| Intangible assets | 424.09M |
| Property, plant and equipment | 0.00 |
| Total assets | 719.92M |
| Accounts payable | 5.67M |
| Short/Current long term debt | 22.46M |
| Total current liabilities | 23.59M |
| Total liabilities | 44.23M |
| Shareholder's equity | 675.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -69.96M |
| Capital expenditures (TTM) | 3.29M |
| Free cash flow (TTM) | -73.24M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -20.43% |
| Return on Assets | -19.18% |
| Return on Invested Capital | -20.35% |
| Cash Return on Invested Capital | -10.80% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.00 |
| Daily high | 5.30 |
| Daily low | 4.70 |
| Daily Volume | 27K |
| All-time high | 738.72 |
| 1y analyst estimate | 21.50 |
| Beta | 0.82 |
| EPS (TTM) | -2.76 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 15 May 2025 |
Downside potential
Loading...
Downside potential data
| IMMU.ST | S&P500 | |
| Current price drop from All-time high | -99.35% | -12.89% |
| Highest price drop | -99.94% | -56.47% |
| Date of highest drop | 29 May 2024 | 9 Mar 2009 |
| Avg drop from high | -68.53% | -11.07% |
| Avg time to new high | 131 days | 12 days |
| Max time to new high | 2367 days | 1805 days |
COMPANY DETAILS
Marketcap
241.73M
Marketcap category
Small-cap
Description
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company has a collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Employees
30
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Mendus AB (FRA:1YG0) extends its cash runway to 2026 while navigating clinical and market hurdles.
February 14, 2025
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as...
December 17, 2024
Mendus AB (STU:1YG0) reports significant progress in clinical trials and manufacturing alliances, despite a Q3 net loss of 23 million.
November 9, 2024